TCRαβ/CD19去除移植中错配相关与全合无关供者比较
本研究比较了98例原发性免疫缺陷病患儿接受TCRαβ+/CD19+去除移植时,全合无关供者(MUD,n=75)与错配相关供者(MMRD,n=23)的结局。两组中性粒细胞和血小板植入分别在第14天和第13天,继发性植入失败率、急性GVHD 2-4级累积发生率、CMV病毒血症发生率、免疫重建动力学及总生存率均无显著差异。结论认为MMRD与MUD移植结局无差异,在无HLA全合同胞供者时MMRD可考虑作为首选。
要点
- MUD与MMRD组中性粒细胞和血小板植入时间分别为第14天和第13天。
核心结论
- TCRαβ+/CD19+去除移植中,MUD与MMRD的结局无差异。
- 在无HLA全合同胞供者时,MMRD可考虑作为PID患者首选供者。
研究设计与样本
- 回顾性比较98例接受TCRαβ+/CD19+去除移植的儿童PID患者。
- MUD组75例,MMRD组23例。
- 所有患者接受氟达拉滨/曲奥舒凡为基础的预处理,其中73例加用第二种烷化剂。
- 除2例外,其余患者移植前接受抗胸腺细胞球蛋白,并接受短程移植后免疫抑制。
主要发现
- 两组中性粒细胞和血小板植入分别在第14天和第13天。
- CMV疾病发生率为17%,最常见表现为视网膜炎。
临床怎么用
- 在无HLA全合同胞供者时,可优先考虑MMRD进行TCRαβ+/CD19+去除移植。
- MMRD供者获取迅速,可能缩短等待移植时间。
局限性
- 研究为单中心回顾性分析,样本量有限(共98例,MMRD组仅23例)。
- 原文未报告供者类型选择的具体标准及长期随访数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
TCRαβ+/CD19+ graft depletion effectively prevents graft-versus-host disease (GVHD). In the current study, we compared the outcomes of hematopoietic stem cell transplantation (HSCT) with TCRαβ+/CD19+ depletion from matched unrelated donors (MUDs) and mismatched related donors (MMRDs) in patients with primary immunodeficiency (PID). A total of 98 pediatric patients with various PIDs underwent HSCT with TCRαβ+/CD19+ graft depletion from MUDs (n = 75) and MMRDs (n = 23). All patients received a fludarabine-/treosulfan-based conditioning regimen, with 73 also receiving a second alkylating agent. For GVHD prophylaxis, all but 2 received serotherapy (antithymocyte globulin) before HSCT and a short course of posttransplant immunosuppression. Neutrophil and platelet engraftment in both the MUD and MMRD groups occurred on days 14 and 13, respectively. The incidence of secondary graft failure was 0.16 and 0.17 (P = .85), respectively. The cumulative incidence of acute GVHD grade 2 to 4 was 0.17 in the MUD group and 0.22 in the MMRD group (P = .7). The incidence of cytomegalovirus (CMV) viremia was 0.5 in the MUD group and 0.6 in the MMRD group (P = .35). The frequency of CMV disease was high (17%), and the most common manifestation was retinitis. The kinetics of immune recovery was similar in both groups. The overall survival was 0.86 in the MUD group and 0.87 in the MMRD group (P = .95). In our experience, there was no difference in the outcomes of HSCT performed from MUD and MMRD. Hence, given the immediate availability of donors, in the absence of HLA-identical siblings, HSCT with TCRαβ+/CD19+ graft depletion from MMRDs can be considered as the first choice in patients with PID.
引用
- Laberko A, Sultanova E, Gutovskaya E, et al. Mismatched related vs matched unrelated donors in TCRαβ/CD19-depleted HSCT for primary immunodeficiencies. Blood. 2019. PMID: 31558465. doi:10.1182/blood.2019001757
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。